MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2019 International Congress

    Availability of Parkinson’s disease medicines in Ghana: a national survey

    M. Cham, I. Sefah, K. Oppon, R. Odikro, C. Amenorvi, A. Malik, J. Duah, G. Pezzoli, F. Baiden, R. Cilia (Sogakope, Ghana)

    Objective: To determine the affordability, availability, geographic distribution and financing options of Parkinson’s disease (PD) medication in Ghana. Background: In sub-Saharan Africa, patients with PD…
  • 2019 International Congress

    BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

    W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

    Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…
  • 2019 International Congress

    The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

    F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

    Objective: Analyse the effects of levodopa on speech and its possible relationship with motor features and dyskinesias in a group of advanced Parkinson’s disease (PD)…
  • 2019 International Congress

    High cost of medications for Parkinson’s Disease patients in a rural population of Gujarat, India

    A. Pandya, E. Albert-Stone, A. Deb, S. Desai (Worcester, MA, USA)

    Objective: To understand the economic burden of the cost of Parkinson’s Disease (PD) medications for outpatients receiving care at Shree Krishna Hospital (SKH)  in Karamsad,…
  • 2019 International Congress

    Levodopa Effects on Visuospatial Working Memory in Parkinson’s Disease

    E. Bayram, I. Litvan, B. Wright, C. Grembowski, D. Harrington (La Jolla, CA, USA)

    Objective: To investigate the effects of levodopa on memory load and distractor resistance during visuospatial working memory (WM) in Parkinson’s disease (PD). Background: Visuospatial WM…
  • 2019 International Congress

    Laboratory Performance of the DopaFuse® Delivery System

    R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

    Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…
  • 2019 International Congress

    Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

    K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

    Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…
  • 2019 International Congress

    Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients

    H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)

    Objective: Since zinc-chelating action of levodopa has been reported in the past, we measured serum zinc level in patients with Parkinson's disease (PD) at our…
  • 2019 International Congress

    Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world

    A. Panwar, N. Sawal (Chandigarh, India)

    Objective: Advanced Parkinson’s disease manifests with  “on-off” phenomenon, dyskinesias and increasing symptom severity . Managing it in developing countries is difficult given the low per…
  • 2019 International Congress

    Impaired fonction of mirror neurons and the role of levodopa in PD patients

    T. Danaila, P. Jaulent, C. Laurencin, J. Xie, H. Klinger, P. Krolak-Salmon, S. Thobois (Lyon, France)

    Objective: Study of the emotional mirroring and its modulation by levodopa treatment in fluctuating PD patients with no significant cognitive burden as assessed by regular…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley